Market Insights
The chronic
kidney disease market trends is expected to grow at a CAGR Of 5.40% during
the forecast period 2022-2030. Rising occurrences of chronic diseases and the
severity of kidney disease has increased the demand for an effective treatment
option for the disease. Causes of chronic diseases are often indicated by
diabetes, polycystic kidney disease, and high blood pressure among others.
Increasing R&D activities with regards
to diagnostics and treatment are expected to offer market growth opportunities
in the future. Moreover, developing economies offer a wider scope for growth
during the forecast period and are expected to affect the market positively.
Increasing prevalence of kidney diseases
and the increased number of biopsy procedures have resulted in high demand for
new diagnostic and treatment options for such chronic diseases. The global chronic
kidney disease market has become highly competitive with the increasing entry
of new market players; this is expected to stimulate growth during the forecast
period. Kidney disease symptoms are often negligible in the initial phases, and
this type of disease is widely referred to as a "silent disease" as
detection often happens when the diseases are progressed to a later stage. This
has increased the need for appropriate diagnostic measures and is driving
market growth.
Regional Analysis
The Americas and Europe are significant
regional markets which have a similar growth pattern. The growth of medical
devices, increasing awareness regarding kidney diseases and the rapid increase
in occurrences of chronic diseases is expected to drive growth in these
regions. Moreover, they display a robust demand for new treatment methods and
options. Opportunities for these markets are being driven by the increasing
emphasis on the development of new drugs. Supportive government legislature
with regards to research & development and the availability of funds for
research in these regions is expected to push the market in a forward
direction.
Asia-Pacific is another important market
due to its rapid growth. Prevalence of diseases such as diabetes and
cardiovascular diseases are driving the demand for appropriate treatment
options. The region has a rapidly improving healthcare sector which has
improved infrastructure, and a wide pool of skilled healthcare professionals.
Demand for advanced treatment technologies and other healthcare technology is
expected to provide the market with opportunities for market expansion.
Market Segmentation
MRFR's the global chronic
kidney disease market report segments on the basis of diagnosis, treatment,
indication, and end-user. By diagnosis, the market is segmented into blood
test, urine test, imaging test, and kidney biopsy. By treatment, the market is
segmented into drugs, dialysis, and kidney transplant. Drugs are further
sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers,
calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the market is segmented into
Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and
others. By end-user, The market is segmented into hospitals and clinics,
diagnostic centers, and others. Globally, the market is divided into the
Americas, Europe, Asia-Pacific & the Middle East and Africa.
Key Players
MRFRs report includes the analysis of
market players participating in the global chronic kidney diseases competitive
landscape. Top market players include Hoffman-La Roche Ltd., Abbott,
AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to
name a few.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Insights
The chronic
kidney disease market trends is expected to grow at a CAGR Of 5.40% during
the forecast period 2022-2030. Rising occurrences of chronic diseases and the
severity of kidney disease has increased the demand for an effective treatment
option for the disease. Causes of chronic diseases are often indicated by
diabetes, polycystic kidney disease, and high blood pressure among others.
Increasing R&D activities with regards
to diagnostics and treatment are expected to offer market growth opportunities
in the future. Moreover, developing economies offer a wider scope for growth
during the forecast period and are expected to affect the market positively.
Increasing prevalence of kidney diseases
and the increased number of biopsy procedures have resulted in high demand for
new diagnostic and treatment options for such chronic diseases. The global chronic
kidney disease market has become highly competitive with the increasing entry
of new market players; this is expected to stimulate growth during the forecast
period. Kidney disease symptoms are often negligible in the initial phases, and
this type of disease is widely referred to as a "silent disease" as
detection often happens when the diseases are progressed to a later stage. This
has increased the need for appropriate diagnostic measures and is driving
market growth.
Regional Analysis
The Americas and Europe are significant
regional markets which have a similar growth pattern. The growth of medical
devices, increasing awareness regarding kidney diseases and the rapid increase
in occurrences of chronic diseases is expected to drive growth in these
regions. Moreover, they display a robust demand for new treatment methods and
options. Opportunities for these markets are being driven by the increasing
emphasis on the development of new drugs. Supportive government legislature
with regards to research & development and the availability of funds for
research in these regions is expected to push the market in a forward
direction.
Asia-Pacific is another important market
due to its rapid growth. Prevalence of diseases such as diabetes and
cardiovascular diseases are driving the demand for appropriate treatment
options. The region has a rapidly improving healthcare sector which has
improved infrastructure, and a wide pool of skilled healthcare professionals.
Demand for advanced treatment technologies and other healthcare technology is
expected to provide the market with opportunities for market expansion.
Market Segmentation
MRFR's the global chronic
kidney disease market report segments on the basis of diagnosis, treatment,
indication, and end-user. By diagnosis, the market is segmented into blood
test, urine test, imaging test, and kidney biopsy. By treatment, the market is
segmented into drugs, dialysis, and kidney transplant. Drugs are further
sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers,
calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the market is segmented into
Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and
others. By end-user, The market is segmented into hospitals and clinics,
diagnostic centers, and others. Globally, the market is divided into the
Americas, Europe, Asia-Pacific & the Middle East and Africa.
Key Players
MRFRs report includes the analysis of
market players participating in the global chronic kidney diseases competitive
landscape. Top market players include Hoffman-La Roche Ltd., Abbott,
AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to
name a few.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Insights
Market Research Future (MRFR) has released a report on the global chronic kidney disease which projects a moderate CAGR of 5.2% during the assessment period of 2017 to 2023. Rising occurrences of chronic diseases and the severity of kidney disease has increased the demand for an effective treatment option for the disease. Causes of chronic diseases are often indicated by diabetes, polycystic kidney disease, and high blood pressure among others.
Increasing prevalence of kidney diseases and the increased number of biopsy procedures have resulted in high demand for new diagnostic and treatment options for such chronic diseases. The global chronic kidney disease market has become highly competitive with the increasing entry of new market players; this is expected to stimulate growth during the forecast period. Kidney disease symptoms are often negligible in the initial phases, and this type of disease is widely referred to as a "silent disease" as detection often happens when the diseases are progressed to a later stage. This has increased the need for appropriate diagnostic measures and is driving market growth.
Increasing R&D activities with regards to diagnostics and treatment are expected to offer market growth opportunities in the future. Moreover, developing economies offer a wider scope for growth during the forecast period and are expected to affect the market positively.
Market Segmentation
MRFR's report segments the global chronic kidney disease market on the basis of diagnosis, treatment, indication, and end-user. By diagnosis, the market is segmented into blood test, urine test, imaging test, and kidney biopsy. By treatment, the market is segmented into drugs, dialysis, and kidney transplant. Drugs are further sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, apol1 mediated kidney diseases and others. By end-user, The market is segmented into hospitals and clinics, diagnostic centers, and others. Globally, the market is divided into the Americas, Europe, Asia-Pacific & the Middle East and Africa.
Regional Analysis
The Americas and Europe are significant regional markets which have a similar growth pattern. The growth of medical devices, increasing awareness regarding kidney diseases and the rapid increase in occurrences of chronic diseases is expected to drive growth in these regions. Moreover, they display a robust demand for new treatment methods and options. Opportunities for these markets are being driven by the increasing emphasis on the development of new drugs. Supportive government legislature with regards to research & development and the availability of funds for research in these regions is expected to push the market in a forward direction.
Asia-Pacific is another important market due to its rapid growth. Prevalence of diseases such as diabetes and cardiovascular diseases are driving the demand for appropriate treatment options. The region has a rapidly improving healthcare sector which has improved infrastructure, and a wide pool of skilled healthcare professionals. Demand for advanced treatment technologies and other healthcare technology is expected to provide the market with opportunities for market expansion.
Key Players
MRFRs report includes the analysis of market players participating in the global chronic kidney diseases competitive landscape. Top market players include Hoffman-La Roche Ltd., Abbott, AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to name a few.
Latest Industry News
Researchers of the Loyola Medicine and Loyola University, Chicago Stritch School of Medicine, have found that medical nutrition therapy is the most important effective way to slow the progression of kidney diseases and prevent failure of the organs.
Johnson & Johnson has recorded highly positive data from the phase III of its chronic kidney diseases study of the drug Invokana. The company plans to release details regarding findings at a scientific conference soon.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.